Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Nabi Biopharmaceuticals reports results from phase II NicVAX vaccine study

Oct. 18, 2012

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Sep. 28, 2012

University of Pittsburg presents new radioprotectants

Sep. 17, 2012

Pivotal pharmacokinetic study of BEMA-buprenorphine/naloxone meets objectives

Sep. 14, 2012

Orexo submits NDA for sublingual buprenorphine/naloxone product

Sep. 7, 2012

New funding supports Cellerant's development of CLT-008

Sep. 5, 2012

NIDA to fund phase II methamphetamine addiction trial of MN-166

Sep. 5, 2012

Orexo plans NDA for sublingual buprenorphine/naloxone product

Aug. 22, 2012

FDA approves new dosages of sublingual film for opioid dependence

Aug. 21, 2012

Pivotal BEMA-buprenorphine/naloxone trial advances

Aug. 21, 2012

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...